QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Résumé Extracto Full Text PDF Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Articles Ahead of Print [Order Reprint] Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Johnson, T. N Articles by Canada, T. W Search for Related Content PubMed PubMed Citation Articles by Johnson, T. N Articles by Canada, T. W

Etomidate Use for Cushing's Syndrome Caused by an Ectopic Adrenocorticotropic Hormone-Producing Tumor

Critical Care/Nutrition Support Pharmacy Specialist, Division of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, TX

Todd W Canada, PharmD BCNSP

Clinical Coordinator and Director, Critical Care/Nutrition Support Residency, Division of Pharmacy, The University of Texas MD Anderson Cancer Center

Reprints: Dr. Johnson, Division of Pharmacy, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Unit 90, Houston, TX 77030, fax 713/794-4399, tnjohnso{at}mdanderson.org

OBJECTIVE: To report the preparation and use of etomidate in a patient with Cushing's syndrome caused by an ectopic adrenocorticotropic hormone (ACTH)-producing tumor.

CASE SUMMARY: A 73-year-old man with a 5 year history of prostate cancer was admitted for symptoms consistent with Cushing's syndrome. He was started on oral metyrapone for elevated serum cortisol, ACTH, and 24 hour urinary unbound cortisol levels. Shortly after starting metyrapone, he was transferred to the medical intensive care unit for new-onset atrial fibrillation, neutropenic fever, and respiratory failure. A nasogastric tube could not be inserted to administer metyrapone. Intravenous etomidate 4 mg/h (0.06 mg/kg/h) was initiated to decrease cortisol production and provide sedation for mechanical ventilation. Despite supportive treatment, the patient died from multiple organ dysfunction.

DISCUSSION: For patients exhibiting signs and symptoms of Cushing's syndrome who have no enteral access, administering etomidate intravenously may be a viable alternative treatment route. Although several articles report the use of etomidate to control cortisol overproduction, the intravenous preparation and stability are discussed only vaguely. In our patient, etomidate was infused via a 30 mL syringe, 2 mg/mL undiluted through a central venous catheter; syringe use was limited to 24 hours. Etomidate should be infused only with continuous monitoring of hemodynamics and periodic assessment of adrenal function.

CONCLUSIONS: When oral or enteral medications cannot be administered and sedation is required in critically ill patients, etomidate is an appropriate intravenous agent for hypercortisolemia. There were no obvious problems with stability when undiluted etomidate 2 mg/mL was infused through a dedicated central venous catheter lumen.

Key Words: Cushing's syndrome, ectopic adrenocorticotropic hormone, etomidate

Published Online, January 9, 2007. www.theannals.com, DOI 10.1345/aph.1H365

This article has been cited by other articles:

				I. Veytsman, L. Nieman, and T. Fojo Management of Endocrine Manifestations and the Use of Mitotane As a Chemotherapeutic Agent for Adrenocortical Carcinoma J. Clin. Oncol., September 20, 2009; 27(27): 4619 - 4629. [Abstract] [Full Text] [PDF]

				A. Dabbagh, N. Sa'adat, and Z. Heidari Etomidate Infusion in the Critical Care Setting for Suppressing the Acute Phase of Cushing's Syndrome Anesth. Analg., January 1, 2009; 108(1): 238 - 239. [Abstract] [Full Text] [PDF]

				B. M. K. Biller, A. B. Grossman, P. M. Stewart, S. Melmed, X. Bertagna, J. Bertherat, M. Buchfelder, A. Colao, A. R. Hermus, L. J. Hofland, et al. Treatment of Adrenocorticotropin-Dependent Cushing's Syndrome: A Consensus Statement J. Clin. Endocrinol. Metab., July 1, 2008; 93(7): 2454 - 2462. [Abstract] [Full Text] [PDF]